THERAPEUTIC AND PREVENTIVE AGENT FOR HCV

摘要

The inventors of this application carried out an investigation of the HCV replicon inhibitory activity of U18666A and found that the compound has an effect on inhibiting the replication of HCV replicon RNA or the expression of HCV protein. Further, when the inventors carried out a knockdown experiment of DHCR24 using siRNA, it was found that the HCV replicon activity and HCV protein expression are significantly inhibited in a cell in which DHCR24 expression is suppressed. Base on these findings, it was revealed that HCV infection can be treated or prevented by inhibiting an enzymatic activity related to the process of cholesterol biosynthesis.